CANF Key Statistics, Chart & Performance
The current stock price of CANF is 4.07 USD. In the past month the price increased by 11.72%. In the past year, price decreased by -86.15%.
CANF Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CANF. When comparing the yearly performance of all stocks, CANF is a bad performer in the overall market: 97.84% of all stocks are doing better.
CANF Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CANF. The financial health of CANF is average, but there are quite some concerns on its profitability.
CANF Financial Highlights
Over the last trailing twelve months CANF reported a non-GAAP Earnings per Share(EPS) of -14.47. The EPS increased by 39.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -102.07% | ||
| ROE | -188.34% | ||
| Debt/Equity | 0 |
CANF Forecast & Estimates
CANF Ownership
About CANF
Company Profile
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Company Info
CAN FITE BIOPHARMA LTD-ADR
10 Bareket Street, Kiryat Matalon, P.O. Box 7537
Petah Tikva 4951778 IL
CEO: Pnina Fishman
Employees: 5
Phone: 97239241114
CAN FITE BIOPHARMA LTD-ADR / CANF FAQ
Can you describe the business of CAN FITE BIOPHARMA LTD-ADR?
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
What is the stock price of CAN FITE BIOPHARMA LTD-ADR today?
The current stock price of CANF is 4.07 USD. The price decreased by -0.73% in the last trading session.
What is the dividend status of CAN FITE BIOPHARMA LTD-ADR?
CANF does not pay a dividend.
How is the ChartMill rating for CAN FITE BIOPHARMA LTD-ADR?
CANF has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the market capitalization of CANF stock?
CAN FITE BIOPHARMA LTD-ADR (CANF) has a market capitalization of 3.47M USD. This makes CANF a Nano Cap stock.